# Ipamorelin FAQ: Half-Life, Onset, Safety, and the CJC-1295 Pairing > Ipamorelin FAQ: direct, cited answers on half-life, how long it takes to work, FDA status, the CJC-1295 combination, appetite, IGF-1, and the safety questions people ask. The questions people actually ask, each with a short, cited answer drawn only from the published record. ## How to reconstitute CJC-1295 ipamorelin 5mg? Only general research-handling context applies here, not a preparation protocol. Ipamorelin is supplied as a lyophilized (freeze-dried) powder, free base or acetate salt, and is reconstituted with bacteriostatic water for research handling; as a peptide it degrades with heat and repeated freeze-thaw, so solution is kept refrigerated [2]. This site gives no volumes, concentrations, or steps, because that would cross into dosing guidance. ## How long does ipamorelin stay in your system? The terminal half-life in healthy human volunteers was about 2 hours after intravenous dosing, with clearance 0.078 L/h/kg [2]. By the four-to-five-half-life rule of thumb, the peptide is largely cleared from blood in roughly 8 to 10 hours. Urine metabolites remain detectable by anti-doping laboratories longer than the parent peptide persists in blood [11]. ## How long does it take for ipamorelin to work? The growth-hormone pulse it triggers peaks about 40 minutes after a dose in humans — that is the only rigorously measured onset figure [2]. Subjective effects people report, such as deeper sleep, are typically described over one to two weeks in research-use communities, but those accounts are anecdotal, not clinical evidence, and were never confirmed in a controlled trial. ## What is the half-life of ipamorelin? Approximately 2 hours, measured as the terminal half-life in healthy male volunteers given single intravenous doses, alongside a clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The kinetics were dose-proportional across the full studied range, and the GH response was a single pulse peaking near 40 minutes [2]. ## Is ipamorelin available in an oral form? Ipamorelin itself is not orally bioavailable — only engineered Ipamorelin-derived analogs reached around 10% oral absorption in dogs [10]. The studied routes are intravenous, subcutaneous, intranasal (about 20% bioavailability), and intraperitoneal [10]. There is no oral Ipamorelin product supported by the pharmacokinetic literature. ## What is ipamorelin? Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin / growth hormone secretagogue receptor (GHS-R1a) to release a pulse of growth hormone [1]. Its defining feature is selectivity: it raised GH potently in rats and swine without raising ACTH or cortisol even at more than 200-fold its GH ED50 [1]. It is a research peptide, not an approved drug. ## What does ipamorelin do for you? In studies, Ipamorelin triggers a single discrete growth-hormone pulse by activating the ghrelin receptor on pituitary cells [1]. In animals this produced dose-dependent bone growth [4] and reduced chemotherapy-related weight loss in a 2024 ferret model [5]. In the one human efficacy trial, for postoperative ileus, it did not beat placebo [3]. It is described in research terms only — no human use is endorsed here. ## What is ipamorelin peptide? Ipamorelin peptide is a five-amino-acid synthetic compound derived from GHRP-1 by removing its central Ala-Trp dipeptide, with non-natural residues that resist enzymatic breakdown [1]. It is a selective ghrelin-receptor (GHS-R1a) agonist — a ghrelin mimetic that tells the pituitary to release growth hormone [1]. The body does not make it; it is classified as a research peptide, not a medicine. ## What are the risks of ipamorelin? The biggest documented issue is that human evidence is thin and partly negative — the only Phase 2 trial missed its endpoint, and treatment-emergent adverse events occurred in 87.5% of the Ipamorelin arm versus 94.8% on placebo, with no Ipamorelin-specific signal in that short window [3]. Class-level concerns include a cardiotoxicity signal in a related GHS-R1a agonist [6] and theoretical IGF-1/cancer and glycemic concerns. Long-term human safety is uncharacterized. ## Does ipamorelin reduce belly fat? No human trial has tested Ipamorelin for fat loss. In a 2024 ferret study, intraperitoneal Ipamorelin (1-3 mg/kg) reduced chemotherapy-induced body-weight loss by about 24% in the delayed phase via a peripheral mechanism, but that is weight-loss *protection* in a cachexia model, not fat reduction [5]. Community reports of a gradual lean-out are anecdotal and confounded by diet and training [4]. ## What are the downsides of ipamorelin? The central downside is the evidence gap: one failed Phase 2 trial [3], no Phase 3, and no long-term human safety database. Class-level safety concerns include myocardial degeneration seen with a related GHS-R1a agonist in rats [6]. Community-reported downsides — flushing, tingling, mild water retention, increased appetite, injection-site irritation — are anecdotal and detailed on the effects page. ## Why is ipamorelin being discontinued? Ipamorelin was never an approved drug to discontinue; its clinical development simply stopped after the Phase 2 postoperative-ileus trial missed its primary endpoint (25.3 vs 32.6 hours to first tolerated meal, p=0.15) [3]. Separately, in 2024 the FDA removed Ipamorelin acetate from Category 2 of the interim Section 503A bulk-substances list, restricting compounding-pharmacy access — a regulatory tightening, not a product recall. ## What does CJC-1295 and ipamorelin do? The pairing combines a GHRH analog (CJC-1295) with a selective ghrelin-receptor GHRP (Ipamorelin) to stimulate growth hormone through two complementary pathways at once. In animals, GHRH plus a GHRP produced GH peaks greater than the sum of each alone [12]. No controlled human trial of the combination exists, so its effects in people are extrapolated from single-agent pharmacology, not demonstrated [3]. ## Does ipamorelin increase IGF-1? Not reliably in short studies. Growth hormone can raise hepatic IGF-1, but the rat bone-growth study found dose-dependent skeletal effects with no measurable change in total IGF-1 or IGFBPs — implying a partly local, GH-pulse-driven effect rather than a systemic IGF-1 surge [4]. Sustained IGF-1 elevation is more a theoretical concern of chronic dosing than a consistent short-term finding [1]. ## How does CJC-1295 ipamorelin work? Ipamorelin activates the ghrelin receptor (GHS-R1a) on pituitary cells to release GH, while CJC-1295 acts on the separate GHRH receptor; because the two pathways are distinct and complementary, combining them yields a larger GH response than either alone [1]. Animal studies confirm GHRH-plus-GHRP synergy and show that endogenous GHRH tone is required for full GHRP effect [12][13]. ## How much CJC-1295 ipamorelin should I take? No validated human dose exists, and this site gives none. There is no controlled human dosing study of the combination; the subcutaneous "stack" protocols in peptide communities have no peer-reviewed human dosing basis and are anecdotal, not recommended [3]. The science offers mechanism and Ipamorelin's ~2-hour half-life from single IV doses [2], not a milligram figure. ## Does CJC-1295 ipamorelin work? No controlled human trial of the combination has been run, so its human efficacy is unproven rather than disproven. The mechanistic building blocks are solid — GHRH-plus-GHRP synergy that exceeds additive GH release in animals [12] — but Ipamorelin's own single human efficacy trial, for ileus, missed its endpoint [3]. Animal data show real dose-dependent effects, such as bone growth [4]. ## Does ipamorelin make you hungry? It can, by mechanism. Ipamorelin acts on the ghrelin receptor, and ghrelin-receptor agonists activate brain appetite centers and induce feeding in animal studies [17]. Some community users report a noticeable appetite uptick in the hours after a dose, described as milder than with GHRP-6 but still unwelcome for some — that part is anecdotal, not clinical evidence. ## Will I gain weight on ipamorelin? No human study establishes weight gain at research-use exposures. By mechanism, ghrelin-receptor agonism can increase appetite [17], and Ipamorelin showed GH-independent stimulation of adiposity and leptin in mice after two weeks of dosing [18]. In the human ileus trial, no weight-related safety signal emerged in the short 7-day window [3]. Any real-world weight change is confounded by diet and training. ## Does ipamorelin increase appetite? By mechanism it can. As a ghrelin-receptor (GHS-R1a) agonist, Ipamorelin engages the same receptor the hunger hormone uses, and ghrelin-receptor agonists induce feeding via central appetite circuits in animal studies [17]. Community reports describe a post-dose appetite bump that is milder than older GHRPs — anecdotal, not clinical evidence, and not quantified in any human trial. ## What does ipamorelin peptide do? Ipamorelin peptide selectively activates the ghrelin / growth hormone secretagogue receptor (GHS-R1a) to release a single pulse of growth hormone, without raising cortisol or prolactin [1]. In animals this drives dose-dependent bone growth [4] and weight-loss protection in a cachexia model [5]; in the one human efficacy trial it did not beat placebo [3]. Described in research terms only. ## Does ipamorelin cause water retention? Mild water retention is an occasionally reported community effect, described as puffiness in fingers, ankles, or face in the first few weeks and milder than with older GHRPs — anecdotal, not clinical evidence. Mechanistically it is plausible because GH excess is linked to sodium and water retention [3]. No human trial has quantified water retention at research-use exposures. --- A pharmacokinetics-first reading of the Ipamorelin record — the two-hour half-life and the single forty-minute GH pulse logged before anything else, the failed human trial kept in plain view, and the community reports fenced off as unverified; no clinic wired behind the console and nothing here sourced, dosed, prescribed, or sold.